Study | Year | Country | Type of cardiac surgery | Interventions |
---|---|---|---|---|
Isetta et al. [25] | 1993 | France | NR | HD APR (n = 70) vs. LD APR (n = 70) vs. TXA (n = 70) vs. Control (n = 70) |
Blauhut et al. [27] | 1994 | Switzerland | CABG | HD APR (n = 14) vs. TXA (n = 14) vs. Control (n = 14) |
Penta de Peppo et al. [20] | 1995 | Italy | CABG & Valve Sx. | HD APR (n = 15) vs. TXA (n = 15) vs. EACA (n = 15) vs. Control (n = 15) |
Corbeau et al. [23] | 1995 | France | CABG & Valve Sx. | HD APR (n = 43) vs. TXA (n = 41) vs. Control (n = 20) |
Pugh et al. [22] | 1995 | UK | Primary CABG | LD APR (n = 21) vs. TXA (n = 22) vs. Control (n = 23) |
Speekenbrink et al. [21] | 1995 | The Netherlands | Primary CABG | PP APR (n = 15) vs. TXA (n = 15) vs. DIP (n = 12) vs. Control (n = 15) |
Menichetti et al. [24] | 1996 | Italy | Primary CABG | HD APR (n = 24) vs. TXA (n = 24) vs. EACA (n = 24) vs. Control (n = 24) |
Pinosky et al. [33] | 1997 | USA | Primary CABG | TXA (n = 20) vs. EACA (n = 20) vs. Placebo (n = 19) |
Mongan et al. [31] | 1998 | USA | Primary CABG | HD APR (n = 75) vs. TXA (n = 75) |
Hardy et al. [26] | 1998 | Canada | Primary CABG | TXA (n = 42) vs. EACA (n = 46) vs. Placebo (n = 44) |
Eberle et al. [29] | 1998 | Germany | Primary CABG | HD APR (n = 20) vs. EACA (n = 20) |
Misfeld et al. [30] | 1998 | Germany | Primary CABG | LD APR (n = 14) vs. TXA (n = 14) vs. Control (n = 14) |
Casati et al. [28] | 1999 | Italy | Primary CABG & Valve Sx. | HD APR (n = 67) vs. TXA (n = 70) vs. EACA (n = 66) |
Bernet et al. [34] | 1999 | Switzerland | Primary CABG | HD APR (n = 28) vs. TXA (n = 28) |
Nuttall et al. [32] | 2000 | USA | Re-do CABG & Valve Sx. | HD APR (n = 40) vs. TXA (n = 45) vs. TXA+ANH (n = 32) vs Placebo (n = 43) |
Maineri et al. [38] | 2000 | Italy | Primary CABG | TXA (n = 24) vs. EACA (n = 24) |
Wong et al. [37] | 2000 | Canada | Re-do CABG & Valve Sx. | HD APR (n = 39) vs. TXA (n = 38) |
Casati et al. [35] | 2000 | Italy | Primary CABG & Valve & ASD Repair | HD APR (n = 518) vs. TXA (n = 522) |
Greilich et al. [36] | 2001 | USA | Primary CABG | HD APR (n = 24) vs. EACA (n = 23) vs. Placebo (n = 25) |
Ray et al. [6] | 2001 | Australia | CABG & Valve Sx. | LD APR (n = 49) vs. EACA (n = 51) |